182499-90-7

Basic information

• Product Name: Phenol, 2-amino-5-ethyl- (9CI)
• Synonyms: Phenol, 2-amino-5-ethyl- (9CI);4-amino-3-hydroxy(ethyl)benzene
• CAS NO: 182499-90-7
• Molecular Formula: C₈H₁₁NO
• Molecular Weight: 137.17904
• Product Categories: ALCOHOL
• Mol File: 182499-90-7.mol

Chemical Properties

• Boiling Point: 254.829 °C at 760 mmHg
• Flash Point: 107.917 °C
• Appearance: /
• Density: 1.116 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: Phenol, 2-amino-5-ethyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Phenol, 2-amino-5-ethyl- (9CI)(182499-90-7)
• EPA Substance Registry System: Phenol, 2-amino-5-ethyl- (9CI)(182499-90-7)

Safety Data

• Hazardous Substances Data: 182499-90-7(Hazardous Substances Data)

Usage

Uses

Used in Dye Production:
Phenol, 2-amino-5-ethyl(9CI) is used as a chemical intermediate for the production of dyes. Its unique structure allows for the creation of a wide range of colored compounds, making it valuable in the dye industry.
Used in Pharmaceutical Synthesis:
In the pharmaceutical industry, Phenol, 2-amino-5-ethyl(9CI) serves as a key building block for the synthesis of various drugs. Its versatile chemical properties enable the development of new medicinal compounds with potential therapeutic benefits.
Used in Organic Compound Synthesis:
Phenol, 2-amino-5-ethyl(9CI) is utilized as a starting material in the synthesis of other organic compounds. Its reactivity and functional groups make it a valuable component in the creation of a diverse array of chemical products.
Potential Use in Medicine and Biochemistry:
While further research is needed, Phenol, 2-amino-5-ethyl(9CI) may have potential applications in the fields of medicine and biochemistry. Its unique structure and properties could lead to the discovery of new therapeutic agents or contribute to a better understanding of biological processes.

Upstream product

• 101664-28-2 5-ethyl-2-nitrophenol 
• 179542-88-2 N-(4-ethyl-2-hydroxy-phenyl)-acetamide 
• 620-17-7 3-ethylphenol 

Downstream Products

• 182499-15-6 N-[2-Hydroxy-4-ethylphenyl]-N'-[2-bromophenyl] urea 

Relevant articles and documents

Norepinephrine and its metabolites are involved in the synthesis of neuromelanin derived from the locus coeruleus

In order to elucidate the chemical structure of black to brown pigments, neuromelanins (NMs), in the substantia nigra (SN) and the locus coeruleus (LC) in the central nervous system of humans and other mammalian species during aging, chemical degradative methods are powerful tools. HPLC analysis after hydroiodic acid hydrolysis detected aminohydroxyphenylethylamines, aminohydroxyphenylacetic acids, and aminohydroxyethylbenzenes, which confirmed that SN-NM and LC-NM contain melanin derived not only from dopamine and norepinephrine (NE) but also from several other catecholic metabolites, such as 3,4-dihydroxyphenylalanine, 3,4-dihydroxyphenylacetic acid, 3,4-dihydroxymandelic acid, 3,4-dihydroxyphenylethanol, and 3,4-dihydroxyphenylethylene glycol, in addition to the corresponding Cys-derivatives in varying degrees. However, hydroiodic acid hydrolysis showed that LC-NM produced the same degradation products as were detected in SN-NM. Thus, we needed to develop a new chemical detection method to validate the existence of NE in LC-NM. In the present study, we report that HCl hydrolysis of LC-NM in the presence of thioglycolic acid yields new products arising from substitution of the hydroxyl group by thioglycolic acid at the benzyl position of NE and cysteinyl-NE. This is the first chemical evidence showing that NE and cysteinyl-NE are incorporated into LC-NM.

Reduction of the nitro group to amine by hydroiodic acid to synthesize o-aminophenol derivatives as putative degradative markers of neuromelanin

Neuromelanin (NM) is produced in dopaminergic neurons of the substantia nigra (SN) and in noradrenergic neurons of the locus coeruleus (LC). The synthesis of NM in those neurons is a component of brain aging and there is the evidence that this pigment can be involved in the pathogenesis of neurodegenerative diseases such as Parkinson's disease. NM is believed to derive from the oxidative polymerization of dopamine (DA) or norepinephrine (NE) with the participation of cysteine, dolichols and proteins. However, there are still unknown aspects in the chemical structure of NM from SN (SN-NM) and LC (LC-NM). In this study, we designed a new method to synthesize o-aminophenol compounds as putative degradation products of catecholamines and their metabolites which may be incorporated into NM. Those compounds are aminohydroxyphenylethylamine (AHPEA) isomers, aminohydroxyphenylacetic acid (AHPAA) isomers and aminohydroxyethylbenzene (AHEB) isomers, which are expected to arise from DA or NE, 3,4-dihydroxyphenylacetic acid (DOPAC) or 3,4-dihydroxyphenylmandelic acid (DOMA) and 3,4-dihydroxyphenylethanol (DOPE) or 3,4- dihydroxyphenylethyleneglycol (DOPEG), respectively. These o-aminophenol compounds were synthesized by the nitration of phenol derivatives followed by reduction with hydroiodic acid (HI), and they could be identified by HPLC in HI hydrolysates of SN-NM and LC-NM. This degradative approach by HI hydrolysis allows the identification of catecholic precursors unique to SN-NM and LC-NM, which are present in catecholaminergic neurons.

COMPOUNDS AND METHODS FOR INHIBITION OF RENIN, AND INDICATIONS THEREFOR

Compounds active as inhibitors of renin are described, as well as methods of using such compounds to treat diseases and conditions associated with the renin-angiotensin system. Formula (I)

IL-8 RECEPTOR ANTAGONISTS

The present invention relates to novel compounds and a novel use of phenyl ureas in the treatment of disease states mediated by the chemokine Interleukin-8 (IL-8).

IL-8 RECEPTOR ANTAGONISTS

This invention relates to novel compounds and a novel use of phenyl ureas in the treatment of disease scates mediated by the chemokine, Interleukin-8 (IL-8). In particular, this invention relates to the novel compounds of Formula (Ia) and their use in treating chemokine mediated diseases wherein the chemokine binds to an IL-8 a or b receptor. Compounds of Formula (Ia) are represented by the structure: STR1 wherein interalia, X is oxygen or sulfur;Rb is NR 6 R. sub.7, alkcyl, aryl, arylC 1-4 alkyl, aryl C 2-4 alkenyl, heteroaryl, heteroarylC 1-4 alkyl, heteroarylC 2-4 alkenyl, heterocyclic or heterocyclic C 1-4 alkyl, or a heterocyclic C 2-4 alkenyl moiety, camphor, all of which may be optionally substituted; R 1 is independently selected from hydrogen; halogen; nitro; cyano; C 1-10 alkyl; halosubstituted C 1-10 alkyl; C 2-10 alkoxy; halosubstituted C 1-10 alkoxy; azide; (CR. sub.8 R 8)q S(O) t R 4 ; hydroxy; hydroxy substituted C 1-4 alkyl; aryl; aryl C 1-4 alkyl; aryl C 2-10 alkenyl; aryloxy; aryl C 1-4 alkyloxy; heteroaryl; heteroarylalkyl; heteroaryl C 2-10 alkenyl; heteroaryl C 1-4 alkyloxy; heterocyclic; heterocyclic C 1-4 alkyl; heterocyclicC 1-4 alkyloxy; heterocyclic C 2-10 alkenyl; q is 0 or an integer having a value of 1 to 10; n is an integer having a value of 1 to 3;m is an integer having a value of 1 to 3; Y is hydrogen; halogen; nitro; cyano; halosubstituted C 1-10 alkyl; C 1-10 alkyl; C 2-10 alkenyl C. sub.1-10 alkoxy; halosubstituted C 1-10 alkoxy; azide; (CR 8 R. sub.8)qS(O) t R 4, (CR 8 R 8)qOR 4 ; hydorxy; hydroxy substituted C. sub.1-4 alkyl; aryl; aryl C 1-4 alkyl; aryloxy; arylC. sub.1-4 alkyloxy; aryl C 2-10 alkenyl; heteroaryl; heteroarylalkyl; heteroaryl C 1-4 alkyloxy; heteroaryl C 2-10 alkenyl; heterocyclic, heterocyclic C 1-4 alkyl; heterocyclicC 2-10 alkenyl;or a pharmaceutically acceptable salt thereof.